Cited by 2,323COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Open access

Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, Abreu, Paula, Bao, Weihang, Wisemandle, Wayne, Baniecki, MaryLynn, Hendrick, Victoria M., Damle, Bharat, Simón-Campos, Abraham, Pypstra, Rienk, Rusnak, James M.·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2118542PMC PMC8908851

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUNDNirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro. METHODSWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTSA total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group).In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths.Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%).All 13 deaths occurred in the placebo group.The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%).Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONSTreatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.(Supported by Pfizer; ClinicalTrials.govnumber, NCT04960202.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2118542

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.
(2016) · The Lancet · doi:10.1016/s0140-6736(16)30054-x · Cited by 5,212
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.021 · Cited by 2,074
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033

Show all 21 references

Sorted by citations

Items 901–1,000 of 1,002

The Conformational Space of the SARS-CoV-2 Main Protease Active Site Loops Is Determined by Ligand Binding and Interprotomer Allostery
Lee, E., & Rauscher, S. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00575 · Cited by 7
Severe outcomes of COVID-19 among adults with increased risk conditions: A population-based observational study
Dryden‐Peterson, S., Kim, A., Caniglia, E. C., Joyce, M.-R. M., Rubins, D. M., Kim, A. Y., Fangman, J. J. W., Baden, L. R., & Woolley, A. E. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316529 · Cited by 8
Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan
Yuasa, A., Matsuda, H., Fujii, Y., Mugwagwa, T., Kado, Y., Yoshida, M., Murata, K., & Gu, Y. (2025) · Journal of health economics and outcomes research · doi:10.36469/001c.129067 · Cited by 7
SARS-CoV-2 Replication Revisited: Molecular Insights and Current and Emerging Antiviral Strategies
Subong, B. J. J., & Forteza, I. L. (2025) · COVID · doi:10.3390/covid5060085 · Cited by 7
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Streinu‐Cercel, A., Castagna, A., Chang, S., Chen, Y.-S., Koullias, Y., Mozaffarian, A., Hyland, R. H., Humeniuk, R., Caro, L., Davies, S., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf406 · Cited by 10
Maternal‐Fetal Impact of Respiratory Viral Infections: Immune Mechanisms and Clinical Outcomes
Parish, M. A., & Klein, S. L. (2026) · Immunological Reviews · doi:10.1111/imr.70099 · Cited by 7
In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment
Wotring, J. W., McCarty, S. M., Shafiq, K., Zhang, C. J., Nguyen, T., Meyer, S. R., Fursmidt, R. M., Mirabelli, C., Clasby, M. C., Wobus, C. E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081284 · Cited by 7
Real-world effectiveness of oral antivirals for COVID-19
Burdet, C., & Ader, F. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01929-8 · Cited by 7
A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19
Plasse, T. F., Delgado, B., Potts, J., Abramson, D. T., Fehrmann, C., Fathi, R., & McComsey, G. A. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.003 · Cited by 7
Validation of baicalein and oridonin as nonspecific SARS‐CoV ‐2 main protease inhibitors
Yan, H., Zhang, R., Yan, G., Liu, X., Li, N., & Chen, Y. (2023) · Phytotherapy Research · doi:10.1002/ptr.7829 · Cited by 7
Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
Li, Y., Liu, Y. H., Wen, L., Chen, H., Wang, W., Tian, M., Cheng, Y., Xue, H., & Chen, C. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1160929 · Cited by 7
Discovery of novel bicyclic[3.3.0]proline peptidyl α-ketoamides as potent 3CL-protease inhibitors for SARS-CoV-2
Chen, X., Peng, L., Huang, J., Yang, Y., Zhang, H., Wang, Z., Zhu, Z., Wang, J., Zhang, J., Chen, K., et al. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129324 · Cited by 7
A mathematical model of SARS‐CoV‐2 immunity predicts paxlovid rebound
Ranard, B. L., Chow, C. C., Megjhani, M., Asgari, S., Park, S., & Yoram Vodovotz, B. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28854 · Cited by 7
Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein
Liang, T., Xiao, S., Wu, Z., Lv, X., Liu, S., Hu, M., Li, G., Li, P., & Ma, X. (2023) · Viruses · doi:10.3390/v15081666 · Cited by 7
Activation of PXR causes drug interactions with Paxlovid in transgenic mice
Lei, S., Guo, A., Lu, J. L., Qi, Q., Devanathan, A. S., Zhu, J., & Ma, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.001 · Cited by 7
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials
Moser, C., Chew, K. W., Giganti, M. J., Li, J. Z., Aga, E., Ritz, J., Greninger, A. L., Javan, A. C., Ignacio, R. B., Daar, E. S., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad285 · Cited by 7
A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition
Forrestall, K. L., Pringle, E. S., Sands, D. C., Duguay, B. A., Farewell, B., Woldemariam, T. A., Falzarano, D., Pottie, I. R., McCormick, C., & Darvesh, S. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105758 · Cited by 7
Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews
Cruciani, M., Pati, I., Masiello, F., Pupella, S., & Angelis, V. D. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad376 · Cited by 7
Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase III COMET-ICE Study
Subramanian, S., Schnell, G., di Iulio, J., Gupta, A. K., Shapiro, A. E., Sarkis, E. H., Lopuski, A., Peppercorn, A., Aldinger, M., Hebner, C. M., et al. (2023) · Future Virology · doi:10.2217/fvl-2023-0146 · Cited by 7
Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022
Shen, Y., Robertson, M. M., Kulkarni, S., Puzniak, L., Zamparo, J. M., Allen, K. E., Porter, T. M., Qasmieh, S. A., Grov, C., Srivastava, A., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad674 · Cited by 7
The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
Wang, L., Ding, Z., Wang, Z., Zhao, Y., Wu, H., Wei, Q., Gao, L., & Han, J. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010109 · Cited by 7
Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial
Tomazini, B. M., Tramujas, L., Medrado, F. A., Gomes, S. P. D. C., Negrelli, K. L., Murinize, G. S., Santos, R. H. N., Vianna, B. M. P., Piotto, B. F., Veiga, T. S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299197 · Cited by 7
Real‐Life Comparison of Antivirals for SARS‐CoV‐2 Omicron Infection in Patients With Hematologic Malignancies
Aiello, T. F., Peyrony, O., Chumbita, M., Monzó, P., Lopera, C., Puerta‐Alcalde, P., Magnano, L., Fernández‐Avilés, F., Cuesta, G., Tuset, M., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13264 · Cited by 7
Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand
Salvadori, N., Jourdain, G., Krittayaphong, R., Siripongboonsitti, T., Kongsaengdao, S., Atipornwanich, K., Sakulkonkij, P., Angkasekwinai, N., Sirijatuphat, R., Chusri, S., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107021 · Cited by 7
The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants
Hsu, C., Hsu, W., Shiau, B.-W., Tsai, Y., Wu, J., Liu, T., Huang, P., Chuang, M., & Lai, C.-C. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2339398 · Cited by 7
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals
Fisher, L. H., Kee, J. J., Liu, A., Espinosa, C. M., Randhawa, A. K., Ludwig, J., Magaret, C. A., Robinson, S. T., Gilbert, P. B., Hyrien, O., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.12835 · Cited by 8
Tale of Two Polymorphs: Investigating the Structural Differences and Dynamic Relationship between Nirmatrelvir Solid Forms (Paxlovid)
Sadeghi, M. S., Guo, R., Bellucci, M. A., Quino, J., Buckle, E. L., Nisbet, M. L., Yang, Z., Greenwell, C., Gorka, D. E., Pickard, F. C., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01074 · Cited by 7
Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro
Nair, M. S., Luck, M. I., Huang, Y., Sabo, Y., & Ho, D. D. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae385 · Cited by 7
Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19
Wang, K., Li, H., Li, Y., Xu, F., Sun, Z., Yang, Y., Huang, J., & Chen, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1449583 · Cited by 7
A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019
Haslam, A., & Prasad, V. K. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae497 · Cited by 7
Antiviral agents and therapeutics against respiratory viruses
Tripp, R. A., & Martin, D. E. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2401911 · Cited by 7
Clinical Characteristics, Diagnosis and Short-Term Outcomes of COVID-19–Associated Acute Myocarditis in China
Liu, H., Zhou, P., Huang, Y., Yan, S., Zhou, L., Gao, C., Wang, L., Tang, J., Zhou, Q., Li, X., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15048 · Cited by 7
Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
do Carmo, H. R. P., Castillo, A. R., Bonilha, I., Gomes, É. I. L., Barreto, J., Moura, F. A., Davanzo, G. G., Monteiro, L. D. B., Muraro, S. P., de Souza, G. F., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1402032 · Cited by 7
Catalytic Mechanism of SARS-CoV-2 3-Chymotrypsin-Like Protease as Determined by Steady-State and Pre-Steady-State Kinetics
Zhu, J., Kemp, A. M., Chenna, B., Kumar, V., Rademacher, A., Yun, S., Laganowsky, A. D., & Meek, T. D. (2024) · ACS Catalysis · doi:10.1021/acscatal.4c04695 · Cited by 7
Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier
Zhao, L., Li, C., Wang, M., Zhou, M., Jiang, L., Zhang, W., Yu, J., Wang, W., Zhou, K., Pan, K., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01556-24 · Cited by 7
SARS‐CoV‐2 vaccine clinical efficacy in SOT: What we know and our current gaps
Sigler, R., & Aslam, S. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13809 · Cited by 7
COVID-19 can be called a treatable disease only after we have antivirals
Zhang, X., Horby, P., & Cao, B. (2022) · 中国科学通报：英文版 · doi:10.1016/j.scib.2022.02.011 · Cited by 7
Treatment strategies of COVID-19: A rheumatology perspective
Drosos, A. A., Pelechas, E., & Voulgari, P. V. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.05.014 · Cited by 7
Outpatient Antibiotic and Antiviral Utilization Patterns in Patients Tested for Respiratory Pathogens in the United States: A Real-World Database Study
Tse, J. Y. M., Near, A. M., Cheng, M. M., Karichu, J. K., Lee, B., & Chang, S. (2022) · Antibiotics · doi:10.3390/antibiotics11081058 · Cited by 7
Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics
Battaglini, D., Cruz, F. F., Robba, C., Pelosi, P. P., & Rocco, P. R. M. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2120801 · Cited by 7
Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients
Karolyi, M., Kaltenegger, L., Pawelka, E., Kuran, A., Platzer, M., Totschnig, D., König, F., Hoepler, W., Laferl, H., Omid, S., et al. (2022) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02098-9 · Cited by 7
Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients
Yetmar, Z. A., Bhaimia, E., & Razonable, R. R. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000981 · Cited by 7
COVID-19 in Patients with Hematologic Diseases
Casetti, I. C., Borsani, O., & Rumi, E. (2022) · Biomedicines · doi:10.3390/biomedicines10123069 · Cited by 8
Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea
Jeon, J., & Chin, B. S. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e352 · Cited by 7
Use of Antiviral Agents and other Therapies for COVID-19
Blaskovich, M. A. T., & Verderosa, A. D. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1758837 · Cited by 7
Early Racial and Ethnic Disparities in the Prescription of Nirmatrelvir for COVID-19
Tarabichi, Y., Kaelber, D. C., & Thornton, J. D. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07844-3 · Cited by 7
Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir
Greenfield, S. R., Eng, H. F., Yang, Q., Guo, C., Byrnes, L. J., Dantonio, A. L., West, G. M., Di, L., & Kalgutkar, A. S. S. (2023) · Xenobiotica · doi:10.1080/00498254.2023.2183158 · Cited by 7
Paxlovid-Induced Tacrolimus Toxicity in the Treatment of COVID-19: A Case Report
Michael, S., Heilbronner, R., Lloyd, C. M., & Levitin, H. W. (2023) · Cureus · doi:10.7759/cureus.35489 · Cited by 7
Facilitating oral COVID-19 therapy utilization through a pharmacy consult service
Portman, D. B., & Scolese, C. J. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.04.010 · Cited by 7
COVID-19: A Pediatric Update in Epidemiology, Management, Prevention, and Long-term Effects
Inagaki, K., & Hobbs, C. V. (2023) · Pediatrics in Review · doi:10.1542/pir.2022-005686 · Cited by 7
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy
Ciccimarra, F., Luxi, N., Bellitto, C., Abbate, L. L., Nardo, P. D., Savoldi, A., Yeomans, A., Molokhia, M., Tacconelli, E., & Trifirò, G. (2023) · BioDrugs · doi:10.1007/s40259-023-00601-w · Cited by 7
Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
Wai, A. K. C., Lee, T. T.-L., Chan, S. C. L., Chan, C. Y., Yip, T. F., Luk, L. Y. F., Ho, J. W. K., So, K. W. L., Tsui, O. W.-K., Lam, M.-L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35068-w · Cited by 7
Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia
Oltolini, C., Acerbis, A., Orofino, G., Racca, S., Noviello, M., Dispinseri, S., Clementi, N., Piemontese, S., Xue, E., Giglio, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1184956 · Cited by 7
A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo
Li, F., Xu, W., Zhang, X., Wang, W., Su, S., Han, P., Wang, H., Xu, Y., Li, M., Fan, L., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04955-3 · Cited by 8
P 1 Glutamine isosteres in the design of inhibitors of 3C/3CL protease of human viruses of the Pisoniviricetes class
Stubbing, L. A., Hubert, J. G., Bell-Tyrer, J. J., Hermant, Y. O., Yang, S. H., McSweeney, A. M., McKenzie-Goldsmith, G. M., Ward, V. K., Furkert, D. P., & Brimble, M. A. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00075c · Cited by 7
Struggling with COVID-19 in Adult Inborn Errors of Immunity Patients: A Case Series of Combination Therapy and Multiple Lines of Therapy for Selected Patients
Bez, P., D’Ippolito, G., Deiana, C. M., Gambier, R. F., Pica, A., Costanzo, G. A. M. L., Garzi, G., Scarpa, R., Landini, N., Cinetto, F., et al. (2023) · Life · doi:10.3390/life13071530 · Cited by 7
The Metabolism of Lufotrelvir, a Prodrug Investigated for the Treatment of SARS-COV2 in Humans Following Intravenous Administration
Cheruvu, N. P. S., van Duijn, E., Spigt, P. A., Barbu, I., Toussi, S. S., Schildknegt, K., Jones, R., & Obach, R. S. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001416 · Cited by 7
Drug–drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS
Qin, F., Wang, H., Li, M., Zhuo, S., & Liu, W. Y. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2239156 · Cited by 7
COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients
Lee, C. Y. S., & Suzuki, J. B. (2023) · Biomedicines · doi:10.3390/biomedicines11072055 · Cited by 7
Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents
Gentry, C. A., Nguyen, P. N., Thind, S. K., Kurdgelashvili, G., & Williams, R. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad504 · Cited by 7
Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follicular lymphoma patient treated with anti-CD20 antibodies
Sakamaki, I., Negoro, E., Iwasaki, H., & Yamauchi, T. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.09.008 · Cited by 7
Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID‐19
Singh, R. S. P., LaBadie, R. R., Toussi, S. S., Shi, H., Berg, J. K., Neutel, J. M., & Aggarwal, S. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2353 · Cited by 7
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
Panza, F., Fiorino, F., Pastore, G., Fiaschi, L., Tumbarello, M., Medaglini, D., Ciabattini, A., Montagnani, F., & Fabbiani, M. (2023) · Microorganisms · doi:10.3390/microorganisms11102607 · Cited by 7
Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal
Xiong, Y., Wang, X., Li, S., Zhang, Q., Guo, L., Chen, W., Zhao, Z., & Liu, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285078 · Cited by 7
Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
Hu, C., Cui, W.-S., Lei, Y. L., Tang, Y.-W., Zhang, Y., Su, Q.-M., Peng, F., Zeng, Y., Song, J., Luo, C.-N., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s433186 · Cited by 7
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Arman, B. Y., Brun, J., Hill, M. L., Zitzmann, N., & von Delft, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010354 · Cited by 8
Antivirals for Broader Coverage against Human Coronaviruses
Outteridge, M., Nunn, C. M., Devine, K. G., Patel, B., & McLean, G. R. (2024) · Viruses · doi:10.3390/v16010156 · Cited by 7
Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant
Cianfarini, C. L., Hassler, L., Wysocki, J. A., Hassan, A., Nicolaescu, V. I., Elli, D., Gula, H., Ibrahim, A. M., Randall, G. C., Henkin, J., et al. (2024) · Cells · doi:10.3390/cells13030203 · Cited by 7
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19
Shah, M. M., Joyce, B., Plumb, I. D., Sahakian, S., Feldstein, L. R., Barkley, E., Paccione, M., Deckert, J., Sandmann, D., Hagen, M. B., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae105 · Cited by 7
SARS-CoV-2 population dynamics in immunocompetent individuals in a closed transmission chain shows genomic diversity over the course of infection
Goldswain, H., Penrice-Randal, R., Donovan-Banfield, I., Duffy, C. W., Dong, X., Randle, N., Ryan, Y., Rzeszutek, A. M., Pilgrim, J., Keyser, E., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01360-1 · Cited by 7
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial
Isa, F., Ortiz, A. M. G., Meyer, J., Hamilton, J. D., Olenchock, B. A., Brackin, T., Ganguly, S., Forleo‐Neto, E., Faria, L., Heirman, I., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00421-3 · Cited by 7
Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections
Petcherski, A., Tingley, B. M., Martin, A., Adams, S. C., Brownstein, A. J., Steinberg, R. A., Shabane, B., Ngo, J., Osto, C. A., Garcia, G., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202403182 · Cited by 7
Initial observations of Jinhua Qinggan Granules, a Chinese medicine, in the mitigation of hospitalization and mortality in high-risk elderly with COVID-19 infection: A retrospective study in an old age home in Hong Kong
Lin, T. P. H., Lau, E. M. C., Wan, K., Zhong, L. L. D., Leung, E., Ko, C. N., Lü, A., Shah, M. R., Bian, Z., & Lam, D. S. C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.948149 · Cited by 7
The emergence of new SARS-CoV-2 omicron subvariants introduces uncertainty about the end of the COVID-19 pandemic
da Silva, S. J. R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1010489 · Cited by 7
MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
Балыкова, Л. А., Селезнева, Н. М., Горшенина, Е. И., Shepeleva, O. I., Kirichenko, N. V., Simakina, E. N., Kolontarev, K. B., DIu, P., Zemskov, D. N., Zaslavskaya, K. Y., et al. (2022) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2022-10-4-371-386 · Cited by 7
COVID-19 in Russia: Evolution of Views on the Pandemic. Report II
Стародубов, В. И., Beregovykh, V. V., Акимкин, В. Г., Семененко, Т. А., Викторовна, У. С., Avdeev, S. N., Zykov, K. A., Трофимова, Т. Н., Вачиковна, П. Н., Переходов, С. Н., et al. (2022) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn2122 · Cited by 7
Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 Mpro Main Protease Inhibitors
Peralta-Moreno, M. N., Anton-Muñoz, V., Ortega-Alarcón, D., Jiménez-Alesanco, A., Vega, S., Abián, O., Velázquez‐Campoy, A., Thomson, T. M., Granadino‐Roldán, J. M., Machicado, C., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16040585 · Cited by 9
Efficacy of the combination of monoclonal antibodies against the SARS-CoV-2 Beta and Delta variants
Boonkrai, C., Cotrone, T. S., Chaisuriyong, W., Tantawichien, T., Thisyakorn, U., Fernandez, S., Hunsawong, T., Reed, M., Wongtangprasert, T., Audomsun, T., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284173 · Cited by 7
Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
Lu, J., Cai, H. N., Hao, Y., Lin, Z., Liu, S., Zhan, Y., Ding, L., Huang, M., Li, Z., Xu, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1161897 · Cited by 7
Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study
Davarpanah, M. A., Adatorwovor, R., Mansoori, Y., Ramsheh, F. S. R., Parsa, A., Hajiani, M., Faramarzi, H., Kavuluru, R., & Asadipooya, K. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02141-0 · Cited by 7
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
Moya, J., Temech, M., Parra, S., Juarez, E., Hernandez-Loy, R., Gutierrez, J. C. M., Diaz, J., Hussain, R., Segal, S., Xu, C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad344 · Cited by 7
Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study
Han, J., Bae, S., Jung, J., Kim, M. J., Chong, Y. P., Lee, S., Choi, S., Kim, Y. S., Chang, E., & Kim, S. (2023) · Medicine · doi:10.1097/md.0000000000035094 · Cited by 7
Does ivermectin have a place in the treatment of mild Covid-19?
Schwartz, E. (2022) · New Microbes and New Infections · doi:10.1016/j.nmni.2022.100985 · Cited by 7
Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: Impact on virus-induced COX-2 expression
Tramontozzi, C., Riccio, A., Pauciullo, S., Frazia, S. L., Rossi, A., & Santoro, M. G. (2024) · Journal of Virus Eradication · doi:10.1016/j.jve.2024.100387 · Cited by 6
Modelling the effectiveness of antiviral treatment strategies to prevent household transmission of acute respiratory viruses
Zaaraoui, H., Schumer, C., Duval, X., Hoen, B., Opatowski, L., & Guedj, J. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012573 · Cited by 6
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation
Wei, Y., Boyer, C., Jia, K. M., Lin, G., Wang, H., Li, C., Hung, C. T., Jiang, X., Yam, C. H. K., Chow, T. Y., et al. (2025) · Emerging Microbes & Infections · doi:10.1080/22221751.2025.2469648 · Cited by 6
Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor
Bardiot, D., McGowan, D. C., Gupta, K., Deval, J., Chang, S. P., Jekle, A., Liu, C., Stevens, S., Serebryany, V., Tauchert, M. J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00088 · Cited by 6
Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna
Brault, A., Kiem, C. T., Couteaux, C., Olié, V., Paireau, J., Yazdanpanah, Y., Ghosn, J., Martin‐Blondel, G., Bosetti, P., & Cauchemez, S. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100634 · Cited by 6
Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors
Tatematsu, D., Akao, M., Park, H., Iwami, S., Ejima, K., & Iwanami, S. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111403 · Cited by 6
Survey of treatment practices for immunocompromised patients with COVID‐19 in Australasia
Moso, M. A., Sasadeusz, J. J., Morrissey, C. O., Bond, K. A., Guy, S., Slavin, M. A., & Dendle, C. (2023) · Internal Medicine Journal · doi:10.1111/imj.16064 · Cited by 6
Absolute Risk Reductions in COVID-19 Antiviral Medication Clinical Trials
Brown, R. B. (2023) · Pharmacoepidemiology · doi:10.3390/pharma2010009 · Cited by 6
Machine learning on large scale perturbation screens for SARS-CoV-2 host factors identifies β-catenin/CBP inhibitor PRI-724 as a potent antiviral
Kelch, M. A., Vera-Guapi, A., Beder, T., Oswald, M., Hiemisch, A., Beil, N., Wajda, P., Ciesek, S., Erfle, H., Toptan, T., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1193320 · Cited by 6
Efficacy of Tixagevimab/Cilgavimab Prophylaxis and Vaccination on Omicron Variants (BA.1, BA.2, BA.5, and BQ.1.1) in Kidney Transplant Recipients
Bertrand, D., Laurent, C., Lemee, V., Lebourg, L., Hanoy, M., Roy, F. L., Nezam, D., Pruteanu, D., Grangé, S., de Nattes, T., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000241 · Cited by 6
A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases
Leonard, R. A., Rao, V. N., Bartlett, A., Froggatt, H. M., Luftig, M. A., Heaton, B. E., & Heaton, N. S. (2023) · Journal of Virology · doi:10.1128/jvi.00597-23 · Cited by 6
Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants
Pagliano, P., Spera, A. M., Sellitto, C., Scarpati, G., Folliero, V., Piazza, O., Franci, G., Conti, V., & Ascione, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2248879 · Cited by 6
Use of targeted SMS messaging to encourage COVID-19 oral antiviral uptake in South West Victoria
Clarke, N. E., O’Keeffe, J. C., Yerramilli, A., Bartolo, C., Mothobi, N. Z., Muleme, M., McNamara, B. J., O'Brien, D. P., Athan, E., & Hussain, M. A. (2023) · Public Health Research & Practice · doi:10.17061/phrp33342309 · Cited by 6
Approach to hematopoietic cell transplant candidates with respiratory viral detection
Kim, S. R., Waghmare, A., & Hijano, D. R. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1339239 · Cited by 6
Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study
Chen, X., Zhu, Y., Shen, L., Zhou, D., Feng, N., & Tong, Q. (2024) · Journal of Intensive Care Medicine · doi:10.1177/08850666241228841 · Cited by 6
Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study
Luo, W., Li, K., Dai, C., Zhu, W., Lin, J., Lü, F., Chen, Q., Wang, W., Zhuang, Q., & Lin, Y. (2024) · Infection · doi:10.1007/s15010-024-02255-4 · Cited by 6
Protocol implementation during the COVID-19 pandemic: experiences from a randomized trial of stress ulcer prophylaxis
Dennis, B. B., Deane, A. M., Lauzier, F., Zytaruk, N. L., Hardie, M. J., Hammond, N. E., Finfer, S. R., Arabi, Y. M., Marshall, J. C., Saunders, L., et al. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02233-2 · Cited by 6

Authors: Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M.
Affiliations: Pfizer (United States) (US)
From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).
Corresponding author: Hammond, Jennifer
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2022-04-14
Volume: 386
Issue: 15
Pages: 1397-1408
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2118542
PMC: PMC8908851
OpenAlex: W4212904481
Cited by: 2,323
References: 21
Citations by year: 2026: 186 · 2025: 319 · 2024: 517 · 2023: 769 · 2022: 525
FWCI: 261.43
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: nirmatrelvir, COVID-19 pandemic, SARS-CoV-2, Mpro inhibitors, ritonavir, oral antiviral therapy, high-risk adults, non-hospitalized patients, viral load, unvaccinated patients, early treatment, SARS-CoV-2 variants, Omicron variant
MeSH terms: Viral Protease Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Administration, Oral, Adult, Antiviral Agents, Double-Blind Method, Drug Combinations, Hospitalization, Humans, Lactams, Leucine, Nitriles, Proline, Vaccination, Treatment Outcome, Disease Progression, Ritonavir, Viral Load

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks